Clinical Trial Detail

NCT ID NCT04128020
Title Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Sherif Farag
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Azacitidine + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.